WS04.03Stool and symptom testing in colorectal evaluation for neoplasia in cystic fibrosis (SCREEN-CF)

IF 5.4 2区医学 Q1 RESPIRATORY SYSTEM

Journal of Cystic Fibrosis Pub Date : 2025-06-01 DOI:10.1016/j.jcf.2025.03.512

N. Taylor , S. Sivam , J. van Dorst , M.J. Coffey , S. Visser , P. Haber , A. Volovets , C.Y. Ooi

{"title":"WS04.03Stool and symptom testing in colorectal evaluation for neoplasia in cystic fibrosis (SCREEN-CF)","authors":"N. Taylor , S. Sivam , J. van Dorst , M.J. Coffey , S. Visser , P. Haber , A. Volovets , C.Y. Ooi","doi":"10.1016/j.jcf.2025.03.512","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>This study evaluated the utility of faecal calprotectin (FC), tumour pyruvate kinase isoenzyme type M2 (TuM2-PK), and immunochemical faecal occult blood test (iFOBT) for detecting colorectal cancer (CRC) and adenomatous polyps (AP) in people with cystic fibrosis (pwCF), who face elevated CRC and ileocolonic malignancy (ICM) risks. Colonoscopy, the gold standard, carries procedural risks in pwCF, highlighting the need for non-invasive stool biomarkers.</div></div><div><h3>Methods</h3><div>A prospective study of pwCF meeting CRC screening criteria and undergoing colonoscopy at a single Australian centre (2019–2023). Faecal samples for FC, TuM2-PK, and iFOBT were collected within three months of colonoscopy. Colonoscopy findings of AP and/or ICM were recorded. Biomarker cut-offs were determined using receiver operating characteristic (ROC) analysis and Youden's J statistic.</div></div><div><h3>Results</h3><div>Among 49 participants [mean (SD) age 47.8 (8.2) years; 47% male], 24.5% (12/49) had AP and 4.0% (2/49) had ICM. The youngest patient with AP or ICM was 43. Performance of biomarkers in detecting ICM and AP is presented in Tables 1 and 2.</div></div><div><h3>Conclusion</h3><div>This study highlights the prevalence of AP and ICM in pwCF, emphasizing CRC screening importance. All biomarkers performed well for ICM, but FC was the only effective tool for AP detection, offering high sensitivity. FC thresholds may guide colonoscopy decisions in pwCF. Validation in larger cohorts is warranted.</div></div>","PeriodicalId":15452,"journal":{"name":"Journal of Cystic Fibrosis","volume":"24 ","pages":"Page S8"},"PeriodicalIF":5.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cystic Fibrosis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1569199325006083","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

This study evaluated the utility of faecal calprotectin (FC), tumour pyruvate kinase isoenzyme type M2 (TuM2-PK), and immunochemical faecal occult blood test (iFOBT) for detecting colorectal cancer (CRC) and adenomatous polyps (AP) in people with cystic fibrosis (pwCF), who face elevated CRC and ileocolonic malignancy (ICM) risks. Colonoscopy, the gold standard, carries procedural risks in pwCF, highlighting the need for non-invasive stool biomarkers.

Methods

A prospective study of pwCF meeting CRC screening criteria and undergoing colonoscopy at a single Australian centre (2019–2023). Faecal samples for FC, TuM2-PK, and iFOBT were collected within three months of colonoscopy. Colonoscopy findings of AP and/or ICM were recorded. Biomarker cut-offs were determined using receiver operating characteristic (ROC) analysis and Youden's J statistic.

Results

Among 49 participants [mean (SD) age 47.8 (8.2) years; 47% male], 24.5% (12/49) had AP and 4.0% (2/49) had ICM. The youngest patient with AP or ICM was 43. Performance of biomarkers in detecting ICM and AP is presented in Tables 1 and 2.

Conclusion

This study highlights the prevalence of AP and ICM in pwCF, emphasizing CRC screening importance. All biomarkers performed well for ICM, but FC was the only effective tool for AP detection, offering high sensitivity. FC thresholds may guide colonoscopy decisions in pwCF. Validation in larger cohorts is warranted.

查看原文本刊更多论文

粪便及症状检测在评估结直肠囊性纤维化肿瘤中的应用（SCREEN-CF）

目的本研究评估粪便钙保护蛋白（FC）、肿瘤pyruvate kinase同工酶M2型（TuM2-PK）和免疫化学粪便隐血试验（iFOBT）在囊性纤维化（pwCF）患者中检测结直肠癌（CRC）和腺瘤性息肉（AP）的应用价值，这些患者面临CRC和回肠恶性肿瘤（ICM）风险升高。结肠镜检查作为金标准，在pwCF中存在程序风险，强调了对非侵入性粪便生物标志物的需求。方法一项符合CRC筛查标准并在澳大利亚单一中心接受结肠镜检查的pwCF前瞻性研究（2019-2023）。在结肠镜检查后三个月内收集FC、TuM2-PK和iFOBT的粪便样本。记录AP和/或ICM结肠镜检查结果。采用受试者工作特征（ROC）分析和约登J统计量确定生物标志物截断值。结果49例受试者[平均（SD）年龄47.8（8.2）岁；47%（男性），24.5%（12/49）有AP， 4.0%（2/49）有ICM。AP或ICM患者年龄最小为43岁。生物标志物在检测ICM和AP方面的表现见表1和表2。结论本研究突出了AP和ICM在pwCF中的患病率，强调了CRC筛查的重要性。所有生物标志物对ICM都表现良好，但FC是唯一有效的AP检测工具，具有高灵敏度。FC阈值可以指导pwCF患者的结肠镜检查决策。在更大的队列中验证是有必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cystic Fibrosis 医学-呼吸系统

CiteScore

10.10

自引率

13.50%

发文量

1361

审稿时长

50 days

期刊介绍： The Journal of Cystic Fibrosis is the official journal of the European Cystic Fibrosis Society. The journal is devoted to promoting the research and treatment of cystic fibrosis. To this end the journal publishes original scientific articles, editorials, case reports, short communications and other information relevant to cystic fibrosis. The journal also publishes news and articles concerning the activities and policies of the ECFS as well as those of other societies related the ECFS.